Abstract
Humans are exposed to heavy metals through a variety of occupational and non-occupational means. Growing evidence has accumulated that prolonged exposure to these heavy metals is associated with cancer occurrence at various body sites including lung, liver, bladder, colon, and skin. Much research effort has been placed on discovering the mechanisms by which heavy metals induce different kinds of cancers. Results from these mechanistic studies have varied for different metals, but increased activation of signaling pathways is often observed. This review will focus on the signaling molecules including epidermal growth factor receptor (EGFR), phosphatidyl inositol 3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR) in carcinogenesis and cancer progression; and how these molecules are affected by the exposure to heavy metals: arsenic, chromium, nickel, and cadmium. Furthermore, drug targets for the prevention and therapy of cancers induced by heavy metals will be discussed with a focus on drugs that are currently in clinical trials for these targets.
Keywords: AKT, Arsenic, cadmium, cancer, chromium, EGFR, mTOR, nickel, PI3K, p70S6K1
Current Cancer Drug Targets
Title:Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Volume: 13 Issue: 3
Author(s): Richard L. Carpenter and Bing-Hua Jiang
Affiliation:
Keywords: AKT, Arsenic, cadmium, cancer, chromium, EGFR, mTOR, nickel, PI3K, p70S6K1
Abstract: Humans are exposed to heavy metals through a variety of occupational and non-occupational means. Growing evidence has accumulated that prolonged exposure to these heavy metals is associated with cancer occurrence at various body sites including lung, liver, bladder, colon, and skin. Much research effort has been placed on discovering the mechanisms by which heavy metals induce different kinds of cancers. Results from these mechanistic studies have varied for different metals, but increased activation of signaling pathways is often observed. This review will focus on the signaling molecules including epidermal growth factor receptor (EGFR), phosphatidyl inositol 3-kinase (PI3K), AKT, and mammalian target of rapamycin (mTOR) in carcinogenesis and cancer progression; and how these molecules are affected by the exposure to heavy metals: arsenic, chromium, nickel, and cadmium. Furthermore, drug targets for the prevention and therapy of cancers induced by heavy metals will be discussed with a focus on drugs that are currently in clinical trials for these targets.
Export Options
About this article
Cite this article as:
L. Carpenter Richard and Jiang Bing-Hua, Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer, Current Cancer Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1568009611313030004
DOI https://dx.doi.org/10.2174/1568009611313030004 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipid Metabolism and Relevant Disorders to Female Reproductive Health
Current Medicinal Chemistry Synthesis, Radiosynthesis and Metabolism of 131I-Y-c(CGRRAGGSC)
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Patents: An Innovative Approach to Anti-Cancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials The Possible Role of Infertility Drugs in Later Malignancy: A Review
Current Medicinal Chemistry Liposomes as siRNA Delivery Vectors
Current Drug Metabolism HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry How to Inhibit Telomerase Activity for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Subject Index to Volume 5
Current Genomics (Iso)Flav(an)ones, Chalcones, Catechins, and Theaflavins as Anticarcinogens: Mechanisms, Anti-Multidrug Resistance and QSAR Studies
Current Medicinal Chemistry ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases
Current Pharmaceutical Design Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Molecular and Cellular Regulators of Cancer Angiogenesis
Current Cancer Drug Targets Pharmacological Activation of Protein Phosphatase 2 A (PP2A): A Novel Strategy to Fight Against Human Malignancies?
Current Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets miR-143: A Novel Regulator of MyoD Expression in Fast and Slow Muscles of Siniperca chuatsi
Current Molecular Medicine